Latest Healthcare News

Arena REIT reported a robust 17% increase in net operating profit for FY2025, underpinned by strong portfolio management and development activity, while raising its distribution guidance by 5.5% for FY2026.

Arena REIT reported a robust FY25 with net profit up 42% to $81.5 million, driven by rental growth and property revaluations, while raising FY26 distribution guidance by 5.5%. The Group also announced a CEO succession plan amid sustained portfolio expansion and strong capital management.

Nutritional Growth Solutions Ltd has clarified discrepancies in its June 2025 quarterly reports, attributing changes to timing and classification adjustments, while reaffirming its financial health and governance compliance.

Recce Pharmaceuticals’ RECCE 327 Topical Gel shows statistically significant superiority over standard antibiotics in treating antibiotic-resistant burn wounds in preclinical models, advancing its U.S. Department of Defense collaboration.

WAM Capital Limited’s July 2025 update reveals a robust net tangible asset position and a healthy interim dividend, underpinned by strong performances from key holdings ALS and HUB24.

Opyl Limited has formalized its partnership with UK-based Innovatrix Capital, positioning its AI platform TrialKey at the forefront of clinical trial failure insurance. This deal not only validates Opyl’s technology but also opens doors to global biotech markets and valuable data streams.

Anteris Technologies reported solid clinical progress with 130 patients implanted with its DurAVR heart valve and is gearing up for its pivotal PARADIGM trial with 79 qualified sites worldwide. The company also strengthened its leadership with two new board members amid ongoing FDA engagement.

Anteris Technologies Global Corp. reported a $42.7 million net loss for the first half of 2025 amid advancing preparations for its pivotal DurAVR Transcatheter Heart Valve trial. The company’s recent IPO proceeds are fueling R&D and manufacturing scale-up as it targets regulatory approvals.

Tryptamine Therapeutics has locked in $2.6 million in non-dilutive funding to fast-track clinical trials of its lead psilocin-based therapy, TRP-8803, targeting binge eating disorder and other conditions.

Audeara Limited has secured a five-year licensing agreement with Eastech (Huizhou) Co., Ltd. to bring its advanced hearing technology to China’s booming medical device market, leveraging major e-commerce platforms for distribution.

Imagion Biosystems has completed the first tranche of its $3.5 million capital raising, issuing 45 million new shares to strengthen its financial position ahead of a key shareholder vote.

Island Pharmaceuticals has raised $350,000 through an options exercise by substantial shareholder MWP Partners, reinforcing confidence in its antiviral drug development pipeline.